CN107898803A - Application of the cordycepin in anti-trioxypurine medicine is prepared - Google Patents
Application of the cordycepin in anti-trioxypurine medicine is prepared Download PDFInfo
- Publication number
- CN107898803A CN107898803A CN201711181268.XA CN201711181268A CN107898803A CN 107898803 A CN107898803 A CN 107898803A CN 201711181268 A CN201711181268 A CN 201711181268A CN 107898803 A CN107898803 A CN 107898803A
- Authority
- CN
- China
- Prior art keywords
- medicine
- hyperuricemia
- compound
- pharmaceutically acceptable
- cordycepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides the new application of cordycepin and its pharmaceutically acceptable salt, its solvate, its chelate, its non-covalent complex or its prodrug in treatment hyperuricemia and its pathological state of relevant disease and/or the medicine of morbid state is prepared, the treatment for the pathological state and/or morbid state of hyperuricemia and its relevant disease provides new medicament selection.
Description
Technical field
The present invention provides a kind of compound and its pharmaceutically acceptable salt, its solvate, its chelate, its is non-
The new application of covalent complex or its prodrug in anti-trioxypurine.
Background technology
Hyperuricemia is a kind of metabolic disturbance diseases of illness rate high as caused by taking in purine for a long time.It is defined
For serum uric acid level>The blood urine acid condition of 6.5 or 7mg/dL (male) or 6mg/dL (women), it and hypertension, hyperlipemia
The generation of disease, atherosclerosis, obesity, gout and kidney trouble etc. is closely related.At present, allopurinol is the most frequently used
Prescription drug, it is xanthine oxidase (XOD) inhibitor.However, it is frequently resulted in as Stevens Johnson are comprehensive
Simulator sickness, renal toxicity, or even fatal hepatic necrosis etc., and it is only effective to about 40% patient.Second of XOD suppresses medicine,
Febuxostat, related with cardiovascular complication, U.S. Food and Drug Administration (FDA) has been required to package insert
Make warning statement.Uricosureic agent, such as probenecid, Sulfinpyrazone and Benzbromarone, directly act on renal tubule urine
Acid transporter GAP-associated protein GAP, suppresses uric acid reabsorption and promotes uric acid renal excretion.But they sometimes due to relevant adverse reaction and
It is restricted, such as allergic reaction, nephrosis and Ismipur toxicity.Therefore, new more effective, safer anti-trioxypurine medicine
Exploitation be highly desirable.
The content of the invention
It is an object of the invention to provide a kind of existing compound and its pharmaceutically acceptable salt, its solvate, its
Chelate, its non-covalent complex or its prodrug are preparing the pathological state for the treatment of hyperuricemia and its relevant disease
And/or the new application in the medicine of morbid state.
To achieve the above object, the technical solution taken of the present invention is：A kind of compound and its pharmaceutically acceptable
Salt, its solvate, its chelate, its non-covalent complex or its prodrug are preparing treatment hyperuricemia and its phase
Application in the pathological state of related disorders and/or the medicine of morbid state, shown in the structural formula such as formula (I) of the compound：
Secondly, present invention also offers a kind of pharmaceutical composition, described pharmaceutical composition contains at least one formula (I) institute
Show compound or the oxide-based derivatives of its N- or its individual isomer or isomer mixture or its is pharmaceutically acceptable
Salt；With at least one pharmaceutically acceptable auxiliary material；
As the preferred embodiment of pharmaceutical composition of the present invention, described pharmaceutical composition can also combine one kind
Or more than one other compounds.
In addition, treat hyperuricemia and its pathological state and/or disease of relevant disease present invention also offers a kind of
The medicine of state, the medicine contain pharmaceutical composition as described above.
Finally, present invention also offers such as structure formula (I) or its pharmaceutically acceptable salt to prepare kinase activity correlation
Application in disease therapeuticing medicine.Preferably, kinase activity related diseases are to be used to prepare hyperuricemia and relative
Pathological state and/or disease state treatments medicine.
The present invention provides cordycepin and its pharmaceutically acceptable salt, its solvate, its chelate, its is non-covalent
Compound or its prodrug are preparing the pathological state for the treatment of hyperuricemia and its relevant disease and/or morbid state
Application in medicine, for the pathological state and/or morbid state of hyperuricemia and its relevant disease treatment provide it is new
Medicament selection.
Brief description of the drawings
Fig. 1 is influence of the compound under single dose to mice serum uric acid concentration.
Fig. 2 is the compound influence to mice serum uric acid concentration at different dosages.
Fig. 3 is influence of the compound to mouse urine uric acid concentration.
Fig. 4 is influence of the compound to mouse blood urea nitrogen.
Fig. 5 is influence of the compound to mouse serum creatinine.
Fig. 6 is influence of the compound various dose to mouse weight.
Fig. 7 is influence of the compound various dose to mouse liver index.
Fig. 8 is influence of the compound various dose to mouse renal index.
Fig. 9 is influence of the compound various dose to mouse spleen index.
Embodiment
To better illustrate the purpose of the present invention, technical solution and beneficial effect, below in conjunction with specific embodiment to this hair
It is bright to be described further.
In general, the compound of the present invention, will be by effectively being treated under any commonly employed and acceptable model of the prior art
Dosage is applied, whether independent medication or with other one or more kinds of medicine drug combinations.Dose therapeutically effective takes
Certainly in the severity of disease, the age of subject and relative health, the efficiency and other factors of compound are used.It is logical
Often, research shows that gratifying result can be obtained from the system research of daily dosage about 1~200mg/kg weight.Greatly
Type mammal, if the definite daily dosage scope of the mankind is about 1~1000mg, can with convenient administration form as point
It is administered into up to 4 dosage (divided doses) daily or sustained release forms.Suitable oral dosage contains about 1~
300mg active ingredients.
The compound of the present invention can be applied as pharmaceutical composition through any conventional administration route, especially：Alimentary canal way
Footpath, for example, it is oral, such as use tablet or Capsule form；Alternatively, parenteral route, such as uses injection or suspension formation,
Local administration is as using lotion, gel, ointment or ointment or nose use or suppository form.The pharmaceutical composition contains this hair
The arbitrary form of bright compound or its pharmaceutically acceptable salt, are aided with more than at least one pharmaceutically acceptable auxiliary material or dilute
Release agent, and by mixing, pelletizing or prepared by the usual manner such as coating method.
For example, peroral dosage form can be tablet or gelatine capsule contains and coexisted with active ingredient：(1) diluent, such as breast
Sugar, glucose, sucrose, mannitol, sorbierite, cellulose, glycine etc.；(2) lubricant, such as silica gel, talcum powder, stearic acid
Or its magnesium salts or calcium salt and/or polyethylene glycol, etc.；(3) adhesive is further included for tablet, such as aluminium-magnesium silicate, gelatinized corn starch, bright
Glue, tragacanth, methylcellulose, carboxy methyl cellulose are received, polyvinyl pyrrolidone etc.；Collapsed if desired, further including (4)
Agent is solved, such as starch, agar, alginic acid or alginate or effervescent agent mixture, etc.；And/or (5) absorbent, colouring agent, perfume (or spice)
Essence and sweetener.Injection type can be aqueous isotonic solutions or supensoid agent, and suppository can be prepared by Fat Emulsion or supensoid agent.
These pharmaceutical compositions can be sterilized and/or contain adjuvant, such as antistaling agent, stabilizer, wetting agent or emulsifying agent, cosolvent,
Adjust the salt and/or buffer solution of osmotic pressure.In addition, they can also include other therapeutic active substances.Suitable percutaneous dosing
The compounds of this invention that formulation contains dose therapeutically effective is simultaneously aided with auxiliary material.What pharmaceutical carrier included easily absorbing can pharmaceutically connect
The solvent received is to assist release action in Host Skin.For example, transdermal administration equipment can include forming bottom in form
Adhesive tape, one is equipped with compound or the container along with auxiliary material, optionally can be administered into host along with a control
The device of speed on skin, so that administration is completed within one section of long period with speed a kind of controllable and set in advance,
And secure the equipment in device on skin.Matrix percutaneous absorption type can also be used.The suitable dosage forms locally used, such as
For skin and eyes, aqueous solution, ointment, emulsifiable paste or gelling agent preferably well known in the art.These formulations, which may contain, to be helped
Solvent, stabilizer, synergist agent, buffer solution and preservative.
The compound of the present invention can combine other one or more kinds of therapeutic agents under dose therapeutically effective and apply together
With (medication combined).For example, with other relief of symptoms materials, non-stay body antiinflammatory drugs, suppress uric acid synthetic drug, suppress
The coordinating effect of uric acid reabsorption Drug combination, such as：Colchicin；Brufen, Voltarol, Indomethacin, Sai Laikao
Former times；Allopurinol, Febustat；The uric acid that Benzbromarone, probenecid, Lesinurad, uricase, rasburicase, PEG are modified
Enzyme.When the compound of the present invention is used in combination with other treatment method, the dosage of compound is administered in combination will depend on certainly
The type of combination medicine used, the specific medicine of use in conjunction, and physical condition of curer etc..
Embodiment 1
Compound (20mg/kg/d) anti-trioxypurine effect under same dose
40 male SPF kunming mices (20 ± 2g, purchased from Nanfang Medical Univ) are taken, are randomly divided into 4 groups：Antihyperuricemic
Disease model control group, positive controls 1, positive controls 2, cordycepin group.Oxygen is injected intraperitoneally according to the dosage of 100mg/kg/d
Piperazine acid potassium salt, while the hypoxanthine modeling of gavage 600mg/kg/d dosage.The previous hour fasting for solids but not liquids of modeling, modeling
Afterwards 1 it is small when, the allopurinol of 1 gavage 5mg/kg/d dosage of positive controls, 2 gavage 7.8mg/kg/d dosage of positive controls
Benzbromarone, the cordycepin of cordycepin group gavage 20mg/kg/d dosage, then gavage is identical for hyperuricemia model control group
The physiological saline of volume, continuous 7 days.After when gastric infusion 1 is small within 7th day, anesthesia plucks eyeball and takes blood, is existed using centrifuge
The isolated serum of 10min is centrifuged under 3500r/min speed, detects uric acid in serum concentration.
The results are shown in Figure 1 (* * represent compared with Normal group, significant difference P<0.01；## is represented and model pair
Compared according to group, significant difference P<0.01).Model control group serum uric acid level reaches 363.1 μm of ol/L.With model group phase
Than positive control drug allopurinol successfully makes high lithemia mice serum uric acid level drop to 129.1 μ from 363.1 μm of ol/L
Mol/L, significance of difference P<0.01, illustrate that business medicine allopurinol successfully makes hyperuricemia mouse blood uric acid water
Pancake is low.Benzbromarone makes high lithemia mice serum uric acid level, and from 105.6 μm of ol/L are reduced to, this is compared with model control group
The significance of difference is P<0.01.Importantly, cordycepin makes high lithemia mice serum uric acid level from being reduced to 264.1 μm of ol/L,
This significance of difference compared with model control group is P<0.01, cordycepin operatively reduces the blood of hyperuricemia mouse
Liquid uric acid level.
From the present embodiment, cordycepin of the present invention has good anti-trioxypurine effect.
Embodiment 2
Oteracil Potassium (98%), hypoxanthine (99%), allopurinol (98%) and Benzbromarone (98%) come from me
Fourth reagent Co., Ltd (Shanghai, China).Cordycepin (99.50%) is purchased from TargetMol companies (Boston, the U.S.).
TRIZOL reagents are to provide (U.S.) by Invitrogen companies.Nanjing Jian Cheng Bioengineering Research Institutes (Nanjing, China) provide
Uric acid level detection kit.Blood urea nitrogen measures creatinine level kit and is bought (Shenzhen, China) from auspicious medical company is stepped.
XOD activity and URAT1 protein levels kit are bought in detection from R＆D companies (U.S.).Animal protocols are micro- by Guangdong Province
Biological study is ratified (gt-iacuc20170228, Guangzhou, China).The male pathogen-free domestic (SPF) used under study for action
Kunming mice (20 ± 2g) is bought from Guangdong Medical Lab Animal Center (Guangzhou, China).
Anti-trioxypurine mouse model positive control is used as by the use of allopurinol and Benzbromarone.Specifically, hyperuricemia is small
It is 100mg/kg that PO dosage is injected intraperitoneally before when mouse 1 is small, while gives the dosage of oral HX 600mg/kg, to improve serum urine
Sour water is put down.Before administration, mouse fasting 1h, but can't help water.In first administration, mouse is first randomly divided into some groups of (N=
10)：Normally, hyperuricemia, allopurinol control group, Benzbromarone control group and administration group.Allopurinol and Benzbromarone
Group mouse gives allopurinol (5 mg/kg) and Benzbromarone control (7.8mg/kg) gavage respectively.Administration group intragastric administration on mice is administered
Respectively in the cordycepin of 15,30,60 mg/kg dosage.
Whole blood and urine are gathered when all mouse are put to death after 7 days.For blood specimen at 4 DEG C, 2400rpm centrifuges 10 min, separation
Serum is simultaneously preserved at -20 DEG C, to measure serum uric acid, serum urea nitrogen and creatinine level.Serum uric acid level assay method with
Based on phosphotungstic acid reaction, the horizontal measure of BUN is based on urase reacts.Liver and nephridial tissue are removed, and are weighed and with cold life
Brine (0.9%) homogenate is managed, in 4 DEG C, 2400rpm centrifugation 10min, supernatant is used for activity and the URAT1 albumen for measuring XOD,
Use enzyme-linked immunosorbent assay kit.Experiment periods (after 7 days), organ is all removed from mouse including liver,kidney,spleen etc..Institute
There is organ to use normal saline flushing, dried with conventional filters after taking-up, then weighed.Acropetal coefficient's (such as liver coefficient
Kidney coefficient and spleen coefficient) expressed as tissue weighting factor, each organ weight divided by single mouse weight by corresponding mouse.
Importantly, as shown in Fig. 2, Oteracil Potassium and hypoxanthine are further proved that successfully induction is high in mouse
Uricacidemia, (high lithemia group serum urea level is increased to 337 μm of ol/ L, P ＜ 0.01 from 202 μm of ol/L of normal group).Pass through
The serum uric acid level for measuring the hyperuricemia mouse of above-mentioned induction is active to assess the anti-trioxypurine of cordycepin.5mg/kg (sun
Property control) allopurinol control group cause hyperuricemia mouse (337 μm of ol/L, P ＜ 0.01) serum uric acid level significant
78 μm of ol/L are reduced to, this is far below normal group (202 μm of ol/L).It is high for the Benzbromarone control group of 7.8mg/kg dosage
Uricacidemia mice serum uric acid level is decreased obviously to 226 μm of ol/L (P ＜ 0.01), close to the level normally organized.It is worth note
Meaning, cordycepin is at 15,30 and 60mg/kg dosage, hyperuricemia mouse (337 μm of ol/L) serum uric acid level point
Do not drop to 216,210 and 203 μm of ol/L (P<0.01), close to normal group.
In order to which the possibility that the hyperuricemia mice serum uric acid level illustrated with cordyceps sinensis extract for treating reduces is due to kidney
The enhancing of uric acid excretion, we detect its influence (Fig. 3) to urine uric acid.PO is a kind of competitiveness for liver uricase
Inhibitor, and the blocking agent of electro physiology urate transporter/passage.In this research, PO inducing mouse uric acid reabsorption rise
With significant reduction (241 μm of ol/L, P of uric acid excretion<0.01), compared with normal group (371 μm of ol/L).Allopurinol causes height
Uricacidemia urine uric acid level further drops to 215 μm of ol/L, P<0.01), this is because allopurinol suppresses in liver
Uric acid generation is reduced caused by XOD activity.Mouse retention uric acid is effectively improved when cordycepin 15,30 and 60mg/kg dosage
Level (303,374 and 403 μm of ol/L, P<0.01).
In order to study influence of the cordycepin to renal function, it is horizontal (Fig. 4) that we have recorded BUN.Normal group and high urine
Acidaemia group BUN is respectively 11.96 and 17.32mmol/L, the statistically significant (P of difference<0.01), show a large amount of PO to kidney
It is dirty to have certain injury.Allopurinol group BUN (17.34mmol/L, P<0.01) it is the 153% of Normal group, but in other purine
Significant difference is not observed between alcohol and high lithemia disease group.Compared with allopurinol group, cordycepin 15 and 30mg/kg treatments
Group, BUN levels are down to 15.93 and 15.82 (P respectively<0.01), there is protective effect to kidney.
The influence of cordycepin and allopurinol to hyperuricemia mice serum creatinine level is as shown in Figure 5.Due to the PO
Substituted by hypoxanthine part, hyperuricemia group serum creatinine level is 61.6 μm of ol/L, hyperuricemia control group with
Normal group (57.9 μm of ol/L, P<0.01) comparing has significant property increase.The cordycepin creatinine level of various dosage is respectively
56.8,52.3 and 55.7, less than high lithemia group (P<0.01) it is, but similar to normally organizing.
Mouse weight data are as shown in Figure 6.Normal group, between high lithemia disease group and cordycepin group weight differences without
Statistical significance.But allopurinol group allopurinol is significant to suppress body weight increase (P<0.05).
Acropetal coefficient (Fig. 7,8,9) of the assessment including liver, kidney and spleen coefficient in mouse.In allopurinol and height
Significant sex differernce (P is observed in liver coefficient between uric acid disease group<0.05).Hyperuricemia group renal function index
(1.23%) it is significantly lower than normal group of (1.36%) (P<0.05).The Kidney coefficients of various dose Cordyceps militaris are respectively 1.41,
1.36 and 1.35%, the indifference compared with normal group.Spleen is the important immune organ of animal, its body-mass index can be opposite
Ground reflects immune function.During this investigation it turned out, compared with Normal group, the significant rise of antihyperuricemic mouse spleen coefficient
(0.41%) (0.36%, P<0.05).It is low, in, the spleen coefficient of high dose cordyceps sinensis is respectively 0.47,0.43 and 0.43%,
Higher than normal group (P<0.05).
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than to the present invention
The limitation of protection domain, although being explained in detail with reference to preferred embodiment to the present invention, those of ordinary skill in the art should
Work as understanding, can be to technical scheme technical scheme is modified or replaced equivalently, without departing from the reality of technical solution of the present invention
Matter and scope.
Claims (5)
1. a kind of compound and its pharmaceutically acceptable salt, its solvate, its chelate, its non-covalent complex or its medicine
Application of the thing precursor in treatment hyperuricemia and its pathological state of relevant disease and/or the medicine of morbid state is prepared,
It is characterized in that, shown in the structural formula of the compound such as formula (I)：
2. a kind of pharmaceutical composition, it is characterised in that containing compound shown at least one formula (I) or its N- is oxide-based spreads out
Biology or its individual isomer or isomer mixture or its pharmaceutically acceptable salt；It is pharmaceutically acceptable with least one
Auxiliary material；
A kind of 3. medicine for the pathological state and/or morbid state for treating hyperuricemia and its relevant disease, it is characterised in that
The medicine contains pharmaceutical composition as claimed in claim 2.
4. one kind compound or its pharmaceutically acceptable salt as shown in structure formula (I) are preparing kinase activity related diseases treatment
Application in medicine；
5. application as claimed in claim 4, it is characterised in that the kinase activity related diseases are hyperuricemia and its phase
The pathological state and/or morbid state of related disorders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711181268.XA CN107898803A (en) | 2017-11-23 | 2017-11-23 | Application of the cordycepin in anti-trioxypurine medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711181268.XA CN107898803A (en) | 2017-11-23 | 2017-11-23 | Application of the cordycepin in anti-trioxypurine medicine is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107898803A true CN107898803A (en) | 2018-04-13 |
Family
ID=61847382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711181268.XA Withdrawn CN107898803A (en) | 2017-11-23 | 2017-11-23 | Application of the cordycepin in anti-trioxypurine medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107898803A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992471A (en) * | 2018-08-28 | 2018-12-14 | 广东粤微生物科技有限公司 | The preparation method of selenium-enriched cordceps militaris extract and its application in preparation inhibiting hyperuricemia and/or oxidation resistant drug or food |
| CN111529597A (en) * | 2020-05-29 | 2020-08-14 | 广东众益康生物科技有限公司 | Traditional Chinese medicine composition for gout and/or hyperuricemia |
| CN112189849A (en) * | 2020-10-28 | 2021-01-08 | 无锡市世纪生物工程有限公司 | Uric acid reducing composition and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539429A (en) * | 2003-10-27 | 2004-10-27 | 中国医学科学院药物研究所 | Deoxyadenosine in aplication of preparing bypolipidemic |
| CN105106959A (en) * | 2015-08-16 | 2015-12-02 | 深圳市倍昂生物科技有限公司 | Application of cordycepin in preparation of pharmaceuticals cooperating with radiotherapy and/or chemotherapy to treat tumors, and pharmaceutical composition |
-
2017
- 2017-11-23 CN CN201711181268.XA patent/CN107898803A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539429A (en) * | 2003-10-27 | 2004-10-27 | 中国医学科学院药物研究所 | Deoxyadenosine in aplication of preparing bypolipidemic |
| CN105106959A (en) * | 2015-08-16 | 2015-12-02 | 深圳市倍昂生物科技有限公司 | Application of cordycepin in preparation of pharmaceuticals cooperating with radiotherapy and/or chemotherapy to treat tumors, and pharmaceutical composition |
Non-Patent Citations (1)
| Title |
|---|
| 申启荣: "中药黄嘌呤氧化酶抑制剂的筛选及抑制动力学研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108992471A (en) * | 2018-08-28 | 2018-12-14 | 广东粤微生物科技有限公司 | The preparation method of selenium-enriched cordceps militaris extract and its application in preparation inhibiting hyperuricemia and/or oxidation resistant drug or food |
| CN111529597A (en) * | 2020-05-29 | 2020-08-14 | 广东众益康生物科技有限公司 | Traditional Chinese medicine composition for gout and/or hyperuricemia |
| CN112189849A (en) * | 2020-10-28 | 2021-01-08 | 无锡市世纪生物工程有限公司 | Uric acid reducing composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535048A (en) | Application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout | |
| CN107898803A (en) | Application of the cordycepin in anti-trioxypurine medicine is prepared | |
| BR112021006002A2 (en) | compositions for the reduction of serum uric acid | |
| CN106619692B (en) | A kind of construction method of acute hyperuricemia animal model | |
| BR112019014924A2 (en) | PHARMACEUTICAL COMPOSITION USED FOR THE TREATMENT OF MYLOPATHY ASSOCIATED WITH HTLV-1 | |
| WO2006118212A1 (en) | Agent for preventing and treating pancreatitis | |
| CN105873579A (en) | Use of cysteamine and derivatives thereof to treat mitochondrial diseases | |
| Gerriets et al. | Febuxostat | |
| CN107753708A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect and preparation method thereof and purposes | |
| CN105640957A (en) | Novel application of itraconazole | |
| CN107753669A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect and preparation method thereof and purposes | |
| CN106562985A (en) | Medicinal health care applications of linarin | |
| CN105311636A (en) | Anti-herpes virus ointment and preparation method thereof | |
| CN110772516A (en) | Application of isocorydine or salt thereof in preparing medicine for reducing blood uric acid level and preventing and treating uric acid nephropathy | |
| CN102485227B (en) | Medicine composition and applications thereof | |
| CN105541838B (en) | A kind of pharmaceutical composition for treating kidney stone | |
| CN103690555B (en) | Pharmaceutical composition for treating acetyl cholinergic urticaria | |
| CN110772517A (en) | Application of boldine or its salt in preparing medicine for reducing blood uric acid level and preventing and treating uric acid nephropathy | |
| CN106692158A (en) | Application of vitamin B1, cordycepic acid and riboflavin and composition thereof in uric acid-lowering drugs | |
| CN104224769B (en) | Application of 1,3,6,7-tetrahydroxy diphenylpyrrone derivative in preparing drug for preventing hyperuricemia and/or gout | |
| CN103638020A (en) | Novel pharmaceutical composition for treating gout | |
| CN106309457B (en) | A kind of ursolic acid-Aspirin Conjugate is preparing the application in liver protecting drug | |
| CN103172622B (en) | The active isomer of silybin bis-bias succinate | |
| CN103610716B (en) | The preparation method of Radix Achyranthis Bidentatae extract and application thereof | |
| CN106943408A (en) | Tetramethyluric acid prevents and treats the application of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180413 |